SWM
CYTK icon

SHP Wealth Management’s Cytokinetics CYTK Stock Holding History

SHP Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7K Buy
20
+9
+82% +$646 ﹤0.01% 1443
2026
Q1 		$725 Buy
+11
New +$699 ﹤0.01% 1547

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SHP Wealth Management's CYTK Position: Q2 2026 in Review

SHP Wealth Management increased its Cytokinetics (CYTK) stake by 82% in Q2 2026, buying an estimated $646 and bringing the position to 20 shares worth $1.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

SHP Wealth Management first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • SHP Wealth Management held 20 shares of Cytokinetics worth $1.7K as of Q2 2026.
  • SHP Wealth Management bought 9 Cytokinetics shares in Q2 2026, an estimated $646.
  • Cytokinetics made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1443 holding.
  • SHP Wealth Management first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.